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half site is active individually or if the site functions as a whole 
unit. Moreover, we identified AGRE-binding proteins according to 
OA human subgroups. 
Methods: Promoter activity was determined by transient rans- 
fection into human OA chondrocytes. AGRE-binding proteins 
were extracted from the EMSA complexes or following passage 
through magnetic beads covalently linked with AGRE-containing 
oligonucleotides and separated by 2-D gel electrophoresis. Pro- 
teins were identified by mass spectroscopy. Two OA subgroups 
have previously been identified and named L-OA chondrocytes 
(low MMP-13 basal levels and high IL-11~-inducibility) and H- 
OA chondrocytes (high MMP-13 basal levels and low IL-11~- 
inducibility). 
Results: i) Mutation(s) in each half site individually reduced the 
promoter activity, indicating that the intact AGRE site is required 
for complete MMP-13 expression, ii) The protein DDB1 (damage 
specific DNA binding protein 1) was identified in the L-OA chon- 
drocyte subgroup, iii) The mutation of the first half of the AGRE 
site (GTGCTGAAAAAG) reproduced the EMSA pattern seen in 
the H-OA chondrocyte subgroup. Mass spectroscopy identified 
p130 TM as one of the proteins in this complex, p130 TM is a dock- 
ing protein known to bind the transcription factor NMP4/CIZ that 
binds the consensus site G/CAAAAA. NMP4 has previously been 
reported to up-regulate some MMP expression. 
Conclusion: Altogether, these data suggest that in H-OA chon- 
drocytes, DDB1 levels may be reduced with or without a con- 
comitant up-regulation of p130cas/NMP4 expression and dis- 
placement of DDB1. These data indicate that the complex 
p130cas/NMP4, by regulating MMP-13 expression, may transform 
the chondrocytes from L-OA into H-OA. 
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Aim of Study: Osteoarthritis (OA) is the most common rheuma- 
tologic disease involving alterations in both proteoglycans and the 
collagen network of cartilage. One of the proteoglycan families is 
the small leucine rich proteoglycans (SLRPs). SLRPs are char- 
acterized by their association with collagen fibrils. Opticin is a 
glycoprotein and class III member of the SLRP family, which was 
initially identified associated with the collagen fibrils of the vitre- 
ous humor of the eye. Because collagen alteration in OA carti- 
lage induces an irreversible degradative process, we first investi- 
gated whether opticin is present in human articular tissues, and 
whether its integrity is maintained in OA cartilage. Furthermore, 
we studied the ability of the key metalloprotease involved in car- 
tilage pathology, MMP-13, to cleave human cartilage opticin. 
Methods: Opticin gene expression was investigated in normal 
and OA human chondrocytes, osteoblasts and synoviocytes by 
real-time PCR. Opticin protein production was determined in nor- 
mal and OA cartilage by immunomorphometry using a specific 
antibody. Opticin was isolated from human cartilage using guani- 
dinium chloride (4 M) extraction, and examined by Western blot- 
ting. Human MMP-13 proteolytic activity on opticin was analysed 
on cartilage extracts incubated for 0-16 hours. 
Results: Opticin was expressed in human chondrocytes, os- 
teoblasts and synoviocytes, and the protein identified in cartilage. 
At the protein level, comparison between normal and OA showed 
that OA cartilage has a slightly higher level of opticin positive 
stained chondrocytes than normal. However, in contrast with OA, 
normal cartilage demonstrated a high level of matrix staining in 
the superficial ayers of the tissue, suggesting that in the OA car- 
tilage matrix, opticin is degraded. Data also showed that cartilage 
opticin could be cleaved by MMP-13 after 16 hours of incubation. 
Conclusion: We demonstrated, for the first time, the expression 
and protein production of opticin in human articular tissues. Our 
data also showed that opticin in OA cartilage is degraded in a pro- 
cess that could be mediated by MMP-13. As SLRPs have been 
reported to regulate collagen fibril diameter and spacing, our data 
suggest that in OA cartilage, the digestion of opticin by MMP- 
13 may result in functional failure of this molecule, consequently 
leading to loss of the collagen fibril properties, predisposing the 
tissue to degeneration particularly at the articular surface. 
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Aim of Study: Bone morphogenic proteins (BMPs) are factors 
that play essential roles during adult bone remodeling and re- 
pair as well as during cartilage formation and maintenance. BMP 
activities are modulated by proteins known as BMP antagonists 
that prevent BMPs from binding to their specific receptors. In this 
study, we investigated the distribution and level of the BMP an- 
tagonist, chordin, in normal and osteoarthritic (OA) cartilage and 
synovial membrane, and the regulation of its expression in chon- 
drocytes and synovial fibroblasts following treatment with inflam- 
matory (IL-11~, TNF-~, IFN-~/) and growth (BMP-2, TGF-I~I, Activin 
A, EGF, bFGF, and PDGF-BB) factors. 
Methods: Localization of chordin in cartilage and synovial mem- 
brane as well as protein levels was performed by immunohisto- 
morphometric analysis on cartilage explants. Gene expression 
was determined using real-time PCR on human chondrocytes 
and synovial fibroblasts. 
Results: In normal cartilage, chordin was found at low levels 
(7.64-1.3% of positive cells) mainly at the very superficial ayers. 
In OA, chordin was also found at the superficial layers (8.94-1.1 %) 
but at a significantly higher level (24.74-1.5%, p<0.0001) in the 
middle and deep layers of the cartilage. Interestingly, chordin also 
demonstrated a differential regulation between normal and OA 
chondrocytes. In contrast to normal cells, chordin was markedly 
(p<0.01) down-regulated in OA chondrocytes by all the growth 
factors tested. IFN-~/ significantly (p<0.0002) stimulated its ex- 
pression in normal, but did not affect chordin in OA chondrocytes. 
However, both cell types were not affected by IL-11~ and TNF-~. 
Protein levels showed patterns similar to those of the mRNAs. 
The distribution and regulation of chordin was similar in normal 
and OA synovial membranes/fibroblasts. 
Conclusion: The increased level of chordin in OA cartilage as 
well as its location and its differential regulation between normal 
and OA chondrocytes uggest a role of this BMP antagonist in the 
OA process. Chordin may reduce the capacity of BMPs to induce 
OA cartilage repair, therefore favoring this tissue catabolism. The 
lack of effect by the inflammatory factors IL-11~ and TNF-~ indi- 
cates that inflammatory processes do not trigger chordin expres- 
sion. 
